faricimab
Sign in to saveAlso known as RO6867461
Faricimab, sold under the brand name Vabysmo ( ), is a monoclonal antibody used for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Faricimab is the first bispecific monoclonal antibody to target both vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2). By targeting these pathways, faricimab stabilizes blood vessels in the retina. It is given by intravitreal injection (injection into the eye) by an ophthalmologist.
Key facts
- Drug.type
- mab
- Drug.image
- Antibodyigg.png
- Drug.mab_type
- mab
- Drug.source
- zu
- Drug.target
- VEGF-A, angiopoietin 2
- Drug.tradename
- Vabysmo
- Drug.DailyMedID
- Faricimab
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- Intravitreal
- Drug.ATC_prefix
- S01
- Drug.ATC_suffix
- LA09
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_CA_comment
- /Schedule D
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.CAS_number
- 1607793-29-2
- Drug.DrugBank
- DB15303
via Wikipedia infobox
Wikidata facts
- Instance of
- monoclonal antibody
- Mass
- 146
Show 1 more fact
- physically interacts with
- vascular endothelial growth factor
via Wikidata · CC0
~5 min read
Encyclopedic overview
18 sectionsContents
- Medical uses
- Adverse effects
- Contraindications
- Special populations
- Pregnancy
- Breast feeding
- Fertility
- Pharmacology
- History
- Society and culture
- Legal status
- Names
- Research
- Neovascular age-related macular degeneration
- Diabetic macular edema
- Branch and central retinal vein occlusion macular edema
- References
- External links
Faricimab, sold under the brand name Vabysmo ( ), is a monoclonal antibody used for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Faricimab is the first bispecific monoclonal antibody to target both vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2). By targeting these pathways, faricimab stabilizes blood vessels in the retina. It is given by intravitreal injection (injection into the eye) by an ophthalmologist.
Faricimab was developed by Roche in Penzberg (Roche Innovation Center Munich). Faricimab was approved for medical use in the United States in January 2022, and in the European Union in September 2022.
Excerpted from Wikipedia’s “faricimab” article, available under the CC BY-SA 4.0 licence.